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The incidence of cerebrovascular disease is highest in the elderly population. However, the pathophysiological mechanisms of brain
response to cerebral ischemia in old age are currently poorly understood. Ischemic changes in the commonly used young animal
stroke models do not reflect the molecular changes associated with the aged brain. Neuroinflammation and oxidative stress are
important pathogenic processes occurring during the acute phase of cerebral ischemia. Free radical generation is also implicated
in the aging process, and the combination of these eects in elderly stroke patients could explain the higher risk of morbidity
and mortality. A better understanding of stroke pathophysiology in the elderly patient would assist in the development of new
therapeutic strategies for this vulnerable age group. With the increasing use of reperfusion therapies, inflammatory pathways
and oxidative stress remain attractive therapeutic targets for the development of adjuvant neuroprotective agents. This paper will
discuss these molecular aspects of acute stroke and senescence from a bench-to-bedside research perspective.
1. Introduction
Old age is an important risk factor for stroke and is associated
with increased patient morbidity and mortality [1, 2]. Many
of these patients have associated comorbidities, for example,
cardiovascular and respiratory disease. This is further com-
plicated by an increased risk of cognitive and functional
decline in elderly stroke patients [3, 4]. Poor functional
recovery has also been demonstrated in aged-animal mod-
els [5]. The pathophysiological mechanisms of the brains
response to an ischemic insult in old age are poorly under-
stood. Most preclinical stroke studies have been performed
in young animal models and therefore do not reflect the
molecular changes associated with the aged brain [6, 7]. This
has been one of the criticisms of preclinical stroke neuro-
protection studies and implicated in the resulting failure of
clinical stroke neuroprotection trials [8, 9].
Neuroprotective therapies targeting NMDA and AMPA
receptors have demonstrated reduced ecacy in aged-animal
stroke models [10]. The pharmacokinetic and pharmaco-
dynamic properties of neuroprotective agents may also be
dierent in older patients [8]. This therefore emphasizes the
importance of assessing potential neuroprotective therapies
in preclinical aged animal stroke models and early clinical
studies of elderly patients [6]. A better understanding of
stroke pathogenesis in the aged brain would assist in the de-
velopment of new therapeutic strategies for treatment of this
vulnerable age group [5, 11].
Acute ischemic stroke triggers an inflammatory cascade
which causes injury to the cerebral tissue, and this process
can continue for several days. Cerebral ischemia results in the
generation of reactive oxygen species (ROS), which induce
the expression of inflammatory cytokines and chemokines.
Cytokines upregulate the expression of cell adhesion mol-
ecules, which leads to leukocyte infiltration of the cerebral
infarct. Cytokines also activate resident microglia, which
leads to increased oxidative stress and the release of matrix
metalloproteinases. These postischemic molecular changes
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lead to dysfunction of the blood-brain barrier (BBB), ce-
rebral edema, and neuronal cell death [12]. The secondary
inflammatory response associated with acute stroke has been
shown to worsen clinical outcome and results in increased
cerebral infarct size [13–15]. Inflammatory mediators and
oxidative stress are also implicated in reperfusion injury after
thrombolysis and mechanical embolectomy, which can result
in further neuronal injury [16, 17]. Furthermore, injury to
the brain can make the body more vulnerable to systemic
infections. A central nervous system injury-induced immun-
odepression syndrome has been identified in experimental
stroke models leading to spontaneous systemic bacterial
infections within 3 days after stroke [18, 19]. This suggests
that early administration of potential neuroprotective thera-
pies (within the first 6 hours) would be the optimal time for
modifying the neuroinflammatory response.
Therapeutic targeting of the neuroinflammatory path-
ways has therefore become an important area of translational
medicine research in acute stroke [16, 17, 20]. The gener-
ation of free radicals and increased oxidative stress is also
implicated in the aging process, and the combination of these
eects in elderly stroke patients could explain the higher
risk of morbidity and mortality [6, 21]. This paper will dis-
cuss the neuroinflammatory aspects of acute ischemic stroke
and senescence from a translational medicine research per-
spective.
2. Inflammatory Mediators in Acute Stroke
The cytokines and chemokines are important inflammatory
mediators which are upregulated within the cerebral tissue
during the acute phase of stroke (Figure 1). As well as being
expressed by cells of the immune system, cytokines are also
produced endogenously by the resident brain cells (microglia
and neurons). Cytokines possess both pro- and anti-inflam-
matory properties, which play an important role in the
progression of the cerebral infarct [22–24]. However, the
spatial and temporal upregulation of cytokines and their
receptors depends on the ischemic model used [25]. The
main cytokines involved in neuroinflammation are the in-
terleukins (IL), IL-1, IL-6, IL-10, and tumor necrosis factor-
α (TNF-α). Cytokines are responsible for the initiation
and regulation of the inflammatory response and play an
important role in leukocyte infiltration into the ischemic
regions of the brain [26–30]. The chemokines, monocyte
chemoattractant protein-1 (MCP-1), and cytokine-induced
neutrophil chemoattractant (CINC) also play an important
role in cerebral ischemia and are potent chemoattractant fac-
tors [31]. In aged rat models of stroke, it has been demon-
strated that the cerebral infarct develops more rapidly after
reversible ischemia, with increased microglial response and
cytokine expression [5, 32, 33]. This results in accelerated
scar tissue formation and is associated with poor functional
recovery [5]. Exacerbation of cerebral injury, via increased
microglial activation, has also been demonstrated in aged-
animal models of intracerebral hemorrhage [34]. The cytok-
ine response has also been demonstrated to increase the risk
of neurodegeneration and cognitive decline in aged animal
models [35, 36]. Cytokines are also implicated in age-related
cerebral atrophy, and an acute-on-chronic cerebral insult is
likely to further exacerbate cognitive decline in old age [37].
3. Cytokine Activation in Acute Stroke
and Senescence
The interleukins (IL-1, IL-6) and TNF-α have been the best-
studied cytokines in the pathogenesis of acute stroke. These
inflammatory mediators have also been implicated in the
aging process [38–40].
3.1. Interleukin-1. The interleukin-1 (IL-1) family consists of
the agonistic isoforms IL-1α and IL-1β, and their endoge-
nous inhibitor, the IL-1 receptor antagonist (IL-1ra) [41].
The expression of IL-1β mRNA is rapidly observed after per-
manent middle cerebral artery occlusion (MCAo) and
remains persistent for several days [42]. The important role
of IL-1β in the pathogenesis of cerebral injury after stroke
has been demonstrated by treatment with IL-1ra, which de-
creases neuronal cell death in the penumbral tissue and
reduces infarct size after permanent focal cerebral ischemia
[43]. The temporal induction profile of IL-1ra after ischemia
virtually parallels that of IL-1β which may suggest that the
balance between IL-1β and IL-1ra is more important than
the levels of IL-1β itself [44].
3.2. IL-1ra in the Treatment of Acute Stroke. The phase II
clinical trial of recombinant human IL-1ra (rhIL-1ra) (An-
akinra or Kineret) demonstrated that patients with cortical
infarcts in the treatment group had a more favorable clinical
outcome (Table 1) [45]. The white cell count and inflam-
matory marker levels were also found to be lower in the
treatment group. There is ongoing research into rhIL-1ra,
as a potential neuroprotective agent in acute ischemic stroke
[46]. A dose-ranging study has been performed in stroke
patients to assess if Anakinra can easily cross the BBB and
reach eective concentrations when administered intrave-
nously. The results were favorable and showed that IL-1ra
can enter the CSF and that the rate of entry can be modulated
by altering the administration regime [47]. If the optimal
therapeutic window can now be determined in acute stroke
patients, this agent might be a promising and eective neu-
roprotective agent.
3.3. Interleukin-6. Interleukin-6 (IL-6) is a proinflammatory
cytokine, which is secreted by monocytes in response to
cerebral injury. Elevated levels of IL-6 in acute stroke patients
correlate with a larger infarct volume and poorer clinical
outcome [15, 58]. Increased IL-6 levels are also associated
with senescence and frailty in old age [38]. This may fur-
ther exacerbate stroke evolution in elderly patients, and this
association of IL-6 with senescence requires further inves-
tigation [32, 35]. However, the role of IL-6 in acute stroke
is far from clear as dierent regulatory levels have been
demonstrated in experimental studies [59]. On one hand, IL-
6 regulates synthesis and expression of acute-phase reactants,
but it also possesses anti-inflammatory eects, which have
been shown to be neuroprotective in both in vitro and in vivo
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Figure 1: Acute cerebral ischemia and neuroinflammation. Acute stroke triggers an inflammatory cascade via the activation of a number of
molecular mediators. The initial phase is associated with the generation of reactive oxygen species (ROS) within the ischaemic cerebral tissue.
This is followed by the release of inflammatory cytokines and chemokines, which subsequently results in activation of resident microglia and
upregulation of cell adhesion molecules (CAMs). The chemokines are involved in the mobilisation of leukocytes, and these inflammatory
cells then interact with the CAMs. This leads to leukocyte infiltration of the ischaemic tissue (diapedesis), which further exacerbates
the inflammatory process. Activation of nuclear factor kappa-B (NF-κB) and inducible nitric oxide synthase (iNOS) results in increased
oxidative stress and further cytokine activation. Release of matrix metalloproteinases (MMPs) from astrocytes and microglia leads to blood-
brain barrier (BBB) dysfunction, cerebral oedema, and neuronal cell death. The aging process further exacerbates these neuroinflammatory
pathways, and this has been associated with increased cognitive decline and poor functional outcome in elderly stroke patients. Therapeutic
targeting of these molecular pathways is an important area of translational medicine research in cerebrovascular disease.
studies [60, 61]. The eects of IL-6 during the dierent stages
of acute stroke and genetic variation may assist in selective
therapeutic targeting of this cytokine [62, 63]. Interestingly,
increased cytokine activity has also been demonstrated in
the muscles of the paretic limb after-stroke, and this may
further hinder recovery [64]. This enhanced inflammatory
state in elderly stroke patients may explain the increased risk
of morbidity and mortality in this age group [65].
3.4. Tumor Necrosis Factor-α. Increased expression of TNF-
α has been demonstrated in experimentally induced stroke
models [66]. The initial source of TNF-α within the ischemic
tissue appears to be from the microglia and macrophages
although it has also been found in ischemic neurons [66, 67].
However, it is important to make a distinction between solu-
ble and membrane-bound TNF-α [68]. Activated microglia
and macrophages are major producers of soluble TNF-α
within the first 6 hours after cerebral ischemia [69]. [70]
TNF-α may show higher production rates in certain regions
(e.g., striatum). Transient MCAo animal models and clinical
stroke studies have also demonstrated increased peripheral
TNF-α levels [22]. Increased levels of TNF-α have also been
associated with senescence and neurodegeneration [36]. In-
tracerebral administration of TNF-α, 24 hours prior to
MCAo, significantly enlarges infarct size, and treatment with
anti-TNF-α antibodies has shown a reduction in infarct size
[66, 71]. Therapeutic targeting of the TNF-α converting
enzyme (TACE) is also being explored as a potential method
of reducing TNF-α expression in acute stroke [72]. However,
as with IL-6, TNF-α has also demonstrated neuroprotective
eects in cerebral injury and could be related to the dierent
stages of stroke pathogenesis [73]. Perhaps most importantly,
TNF-α activates the NF-κB pathway that is involved in sig-
naling cell death (apoptosis) as well as cell survival. NF-κB
will stimulate the production of proinflammatory cytokines
[74]. Ultimately, the balance between the two signals will
determine the toxic degree of TNF-α [75]. Several hypotheses
exist, one suggests that the detrimental eects occur in the
early acute phase of the inflammatory response and the more
beneficial eects in a later subacute stage.
3.5. TNF-α and Neuroprotective Eects in Ischemic Stroke.
TNF-α has demonstrated beneficial eects in ischemic pre-
conditioning when animal models were treated with lipopol-
ysaccharide prior to MCAo [73]. Ischemic preconditioning is
a procedure whereby brief episodes of ischemia are protective
against a subsequent, more severe insult [76]. One factor
that may mediate the neuroprotective eect of ischemic pre-
conditioning is inflammation [77, 78]. Preconditioning with
low doses of the proinflammatory agent lipopolysaccharide
(LPS) in the rat provides a delayed tolerance and neuropro-
tection against subsequent challenge via focal ischemia in
the brain [79, 80]. Likewise, a mild systemic inflammation
elicited prior to stroke in a rat model for periodontitis has
a neuroprotective eect by reducing the infarct volume in a
rat model for cerebral ischemia [81]. It was hypothesized that
the reduction in the infarct volume was due to a reduction in
the number of macrophage-like cells that when present cause
an enlargement of the infarcted area [81]. Two mechanisms
have been put forward to explain the neuroprotective eect
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Table 1: Neuroprotective agents targeting neuroinflammation in acute stroke.
Neuroprotective agent Mode of action Summary of clinical trials
Recombinant human
IL-1 ra (rhIL-1ra)
Interleukin-1 receptor
antagonist
In the phase II clinical trial of rhIL-1ra, patients within 6 hours of stroke
symptom onset were randomised to either rhIL-1ra or placebo. In the
rhIL-1ra-treated group, patients with cortical infarcts had a better clinical
outcome [45].
Enlimomab
Anti-ICAM -1
monoclonal antibody
In the phase III clinical trial of enlimomab, patients were randomised to receive
either the monoclonal antibody or placebo within 6 hours of acute stroke onset.
The modified Rankin scale was worse in patients treated with enlimomab
(P = 0.004), and treatment was associated with higher mortality. Further
development of this drug has been abandoned [28].
UK-279, 276
Neutrophil inhibitory
factor
In the Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN) phase II
clinical trial, patients were randomised to receive either an infusion of UK-279,
276, or placebo within 6 hours of acute stroke symptom onset. No ecacy was
reported on administration of study medication, and the clinical trial was
terminated for futility [48].
Cerovive (NXY-059)
Nitrone-based free radical
trapping agent
In the phase III clinical trial, Stroke-Acute Ischemic—NXY-059 Treatment II
(SAINT II) randomised patients within 6 hours of acute stroke onset to either an
infusion of NXY-059 or placebo. There was no significant reduction in
stroke-related disability, as assessed by the modified Rankin scale (P = 0.33). The
Cerebral Hemorrhage And NXY-059 Treatment (CHANT) trial also showed no
treatment eect on functional outcome.
Further drug development has been abandoned [49, 50].
Edaravone (Radicut) Free radical scavenger
Lacunar stroke patients treated with edaravone showed significant reduction in
infarct size at 1-year followup and early improved neurological outcomes. There
was no dierence in overall clinical outcomes after 1 year [51, 52].
Uric acid Antioxidant
The phase II double-blinded study investigated safety and pharmacokinetics of
uric acid in acute stroke patients treated with rt-PA. Levels of uric acid increased
in the treatment group, with reduction in lipid peroxidation. No safety concerns
were reported with uric acid treatment. Further evaluation is ongoing [53, 54].
Acetaminophen
(Paracetamol)
Antipyretic eect
In the Paracetamol (Acetaminophen) in Stroke (PAIS) clinical trial, patients
presenting within 12 hours of acute stroke onset were randomised to either
acetaminophen (6 g daily) or placebo for three days. There was no benefit seen
for routine use of acetaminophen in acute stroke but post hoc analysis showed
beneficial eects in patients with body temperature between 37 and 39◦C [55].
Minocycline
Bacteriostatic antibiotic
Anti-inflammatory eects
Stroke patients with NIHSS > 5 and symptom onset between 6 and 24 hours
were randomised to either once daily minocycline 200 mg or placebo for 5 days.
The NIHSS and modified Rankin scale were significantly lower in the treatment
group at 90 days [56].
The Minocycline to Improve Neurologic Outcome in Stroke (MINOS) study was
a dose-escalation trial, administering intravenous minocycline within 6 hours of
symptom onset. This was shown to be safe and well tolerated up to 10 mg/kg
intravenous dosing [57].
of proinflammation; one that depends on inducible NO syn-
thase and peroxynitrite [79, 82], and a second one hypothe-
sizing that LPS preconditioning suppresses neutrophil infil-
tration into the brain and microglia/macrophage activation
in the ischemic hemisphere, which is paralleled by sup-
pressed monocyte activation in the peripheral blood [83].
However, ischemic preconditioning via previous transient
ischemic attacks (TIAs) does not seem to have a neuro-
protective eect in elderly stroke patients, and these eects
require further investigation [84]. Both interleukins and
TNF-α are responsible for the activation of inducible nitric
oxide synthase (iNOS), which produces nitric oxide (NO)
and cyclo-oxygenase 2 (COX-2), a free radical producing
enzyme [85]. This increased oxidative stress further worsens
neuronal injury and is also related to the aging process [86].
Selective therapeutic targeting of these cytokines during the
acute phase of stroke may potentially improve functional
recovery. In conclusion, there is no consensus on the eect of
TNF-α after ischemic stroke. Neurotoxic or neuroprotective
eects will depend on several factors such as the extent of
microglial activation in specific brain regions, timing, and
threshold of TNF-α expression and of its receptors, and on
the conditions that stimulate TNF-α signaling [87, 88]. It is
also important to know which form of TNF-α is induced, in
which cells, and on which receptor it will exert its eect.
3.6. Interleukin-10. Interleukin-10 (IL-10) is an anti-inflam-
matory cytokine which inhibits both IL-1β and TNF-α [89].
It has been demonstrated to reduce cerebrovascular risk
in clinical studies of ischemic stroke [90]. IL-10 regulates
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a variety of signaling pathways and promotes neuronal and
glial cell survival by blocking the eects of proapoptotic
cytokines, as well as promoting expression of cell-survival
signals [89]. As IL-10 has been shown to be an anti-inflam-
matory cytokine, exogenous administration of this cytokine
could be a possible therapeutic strategy to reduce cerebral in-
jury after stroke.
3.7. Transforming Growth Factor-β. Transforming growth
factor-β (TGF-β) is another anti-inflammatory cytokine
and is present within microglia [91]. Animal models of
stroke have demonstrated neuroprotective eects of TGF-
β in cerebral ischemia [92]. It is mainly expressed during
the recovery phase of stroke and may contribute to cerebral
remodeling via fibrosis and scar formation. More specifically
after stroke, TGF-β reduces glial activation, decreases the
expression and ecacy of other cytokines, and suppresses
the release of harmful oxygen and nitrogen-derived products.
TGF-β has been shown to reduce infarct volume by attenu-
ating chemokine expression in the ischemic brain of animal
models [93]. However, as TGF-β can inhibit apoptosis of
neurons, but not necrosis, its possible protective influence
is consequently limited to the penumbra. TGF-β could
therefore be neuroprotective by blocking apoptotic pathways
in the ischemic penumbra and aiding recovery of reversible
ischemic brain tissue [94]. On the other hand, TGF-β stim-
ulates glial scar formation and production of beta amyloid
precursor, which can lead to a higher risk of cognitive deficit.
3.8. Granulocyte-Colony Stimulating Factor (G-CSF). The
cytokine growth factor, granulocyte-colony stimulating fac-
tor (G-CSF) has also shown some beneficial eects in aged
animal stroke models, possibly via neurogenesis [95]. G-CSF
promotes leptomeningeal collateral growth after common
carotid artery occlusion and increases circulating blood
monocytes and Mac-2-positive cells suggesting mechanisms
coupled to monocyte upregulation [96]. Moreover, G-CSF
stimulates neuronal dierentiation of adult neural stem cells
in the brain and improves long-term recovery in more chron-
ic stroke models. G-CSF is being further evaluated in clinical
stroke studies [97, 98].
These anti-inflammatory cytokines could therefore play
an important role in potential neurorestorative and neurore-
generative therapies [99]. However, in aged animal models,
there is accelerated gliosis and scar formation after-stroke,
which could reduce the ecacy of these new therapeutic ap-
proaches [5, 100]. TGF-β signaling has been shown to in-
crease in aged animal models of stroke via increased activity
of microglia and astrocytes [101]. The eects of aging and
anti-inflammatory cytokine expression therefore require fur-
ther research in stroke pathogenesis and investigation of po-
tential new treatments in aged animal models [6, 11].
4. Chemokine Expression in Acute Stroke and
Effects of Aging
The chemokines are chemotactic cytokines, which mediate
both leukocyte migration and microglial activation. There
are 40 dierent known chemokines thus far, which all share
a common structural pattern with 4 cysteine residues, which
leads to their classification into four subfamilies of which two
have an important role in stroke pathogenesis: the C-X-C
and C-C family [102]. The C-X-C family attracts neutrophils
and the C-C family monocytes/macrophages [103]. These
are extensively expressed after cerebral ischemia [103, 104].
IL-6 and TNF-α both regulate the expression of MCP-1 and
CINC within the cerebral tissue [104, 105]. Animal and
cell culture studies have also demonstrated that both MCP-
1 and CINC play an important role in ischemia-induced
inflammatory response and cerebral tissue damage [103–
105]. These studies indicate that CINC release precedes neu-
trophil accumulation and that MCP-1 plays a significant role
in the migration of macrophages into the penumbral zone
during cerebral ischemia. Increased MCP-1 levels have also
been associated with aging and increased risk of neurodegen-
eration in animal studies [106].
The maximal expression of MCP-1 has been observed
within 48 hours after-cerebral ischemia [31]. The dierent
temporal production of MCP-1 and CINC contributes to
the regulation of infiltrated leukocytes and the inhibition of
MCP-1 and CINC signalling [103]. These chemokines are
also implicated in BBB dysfunction, which has been demon-
strated to occur earlier in aged rat stroke models [107, 108].
This is associated with accelerated gliosis and scar tissue
formation in aged animals [5, 100]. Modification of this re-
sponse may improve functional recovery and ecacy of po-
tential new neuroregenerative therapies.
4.1. Interleukin-8. IL-8 is also classed as a chemokine
(CXCL8) and is thought to contribute to tissue damage
by activating neutrophil infiltration [109, 110]. Anti-IL-8
antibody was shown to significantly reduce brain oedema
and infarct size [110]. IL-8 has also been shown to be as-
sociated with cerebral atrophy in the aging brain [37]. These
chemokines could therefore be attractive targets for poten-
tial neuroprotective treatments in acute ischemic stroke
[110, 111]. Therapy with a broad spectrum pan-chemokine
inhibitor, given at the onset of reperfusion, can reduce infarct
volume by 50% after a 1-hour MCAo in rats [112]. These
animals showed less macrophage accumulation in the peri-
infarct area, but not in the core of the insult. This sup-
ports the hypothesis that inflammatory cells contribute to
extended damage within the ischemic penumbra.
5. Early Gene Expression in Acute Stroke
Cerebral ischemia and the resulting increased oxidative stress
activate early gene expression. This plays an important role
in the neuroinflammatory response after cerebral injury and
results in the production of cytokines, acute phase proteins,
and other inflammatory mediators [113]. Microarray studies
have demonstrated that over 400 genes could be activated
during cerebral ischemia [113, 114]. One of the important
transcription factors implicated in the inflammatory cascade
is nuclear factor kappa-B (NF-κB). This is a major mediator
in the brain’s response to ischemia and reperfusion and in
the pathogenesis of acute stroke [30, 115]. NF-κB activation
6 Journal of Aging Research
has also been associated with age-related neurodegeneration
[116]. NF-κB is activated by a number of factors that are
present during cerebral ischemia, which include activated
glutamate receptors, reactive oxygen species (ROS), TNF-α,
and IL-1β [115, 117]. NF-κB is an important regulator of the
inflammatory cascade, and many inflammatory mediators
such as inflammatory cytokines, cell adhesion molecules
(CAMs), and iNOS have NF-κB binding sequences in their
promoter regions [118]. It has several dierent targets and
eects in various cell types and tissues, which can appear
paradoxical [119, 120]. In some studies, preventing NF-κB
activation was shown to be protective, whereas in other stud-
ies, activation of NF-κB enhanced neuronal survival [119–
121]. These conflicting results may be due to the fact that NF-
κB can upregulate both proinflammatory and prosurvival
factors that act in dierent ways depending on cell subtype
[121].
Therapeutic targeting of the NF-κB pathway has there-
fore become an attractive treatment option, as a central target
of the neuroinflammatory cascade. Proteasome inhibitors
have shown promising results in animal models of acute
stroke [122]. NF-κB, in its inactive form, is normally com-
plexed to the inhibitory protein, inhibitory κB (IκB). Phos-
phorylation of IκB by IκB kinase (IKK) leads to activation
of NF-κB. Phosphorylated IκB is then ubiquitinated and
subsequently undergoes degradation by the proteasome.
Proteasome inhibition has become an attractive target for
drug discovery research in an attempt to reduce NF-κB
activation by preventing IκB degradation, thus resulting in a
dampening of the inflammatory response [123]. Hypother-
mia has been also shown to attenuate NF-κB transcriptional
activity in aged rat models of stroke, and the use of hypo-
thermia in acute stroke is currently being explored in clinical
trials [124, 125]. However, NF-κB activity may be beneficial
during the recovery phase of stroke and involved in cerebral
remodelling [121]. The eects of cerebral ischemia and
senescence can also result in proteasomal dysfunction, which
can progress to cell death [126, 127]. Therefore, careful eval-
uation of potential drugs targeting the ubiquitin-proteasome
system and NF-κB is required.
6. Sirtuins and Telomerase Effects on
Aging and Neuroprotection
Sirtuin proteins have been associated with longevity and
influence aging by regulation of transcription and apoptotic
factors [128]. Humans possess seven sirtuin proteins with
sirtuin1 (Sirt1) being the best studied. Sirt1 is a deacetylase
enzyme and influences inflammatory pathways via regula-
tion of NF-κB activity [129]. The flavonol compound, ica-
riin, has demonstrated antioxidant activity and neuroprotec-
tion via upregulation of Sirt1 [130]. Resveratrol, a chemical
found in red wine, has been shown to increase activity of
Sirt1 and attenuate inflammatory response in animal models
of stroke [131]. It has also shown neuroprotective eects
via ischemic preconditioning associated with Sirt1 activation
[132]. Resveratrol is being further evaluated in clinical
studies [133].
Telomeres are repetitive sequences of DNA, located at the
end of chromosomes and have a protective role in preventing
chromosomal damage. Telomere attrition is associated with
senescence and exacerbated by oxidative stress [134]. This
has been implicated in the pathogenesis of atherosclerosis
and vascular disease [135]. The telomerase enzyme and
its catalytic subunit telomerase reverse transcriptase (TERT)
maintain telomere length during cell replication. TERT
knockout animal models of stroke have demonstrated en-
hanced neuroinflammatory response and increased infarct
volume [136]. Sirt1 has been shown to have a telomere
protective eect by reducing oxidative stress and maintaining
telomerase activity [137]. The eects of telomerase and Sirt1
are exciting new areas of translational stroke and aging re-
search.
7. Effect of Heat Shock Proteins in Acute Stroke
and Senescence
Heat shock proteins (HSPs) are molecular chaperones, which
play an important role in cellular metabolism. They also
have an important role in controlling the neuroinflammatory
pathways [138]. HSP70 is the major HSP and is constitutively
expressed in neuronal tissue [138]. Neuronal injury and
increased oxidative stress induce HSP70 expression. Animal
HSP70 knockout studies have demonstrated increased cere-
bral infarct size [139]. The HSPs also reduce NF-κB acti-
vation in animal models of cerebral ischemia by interfering
with I-κB phosphorylation by IKK [138]. This attenuates the
neuroinflammatory process, and the neuroprotective eects
of HSPs are being further investigated for potential treatment
in acute stroke [140]. The HSPs have also demonstrated
protective eects from aging and associated with human
longevity [141]. Chaperonotherapies could therefore be an
attractive therapeutic option for neuroinflammatory disease
treatment in old age [142, 143].
8. Cell Adhesion Molecules in Acute
Stroke Pathogenesis
The accumulation and infiltration of the cerebral tissue by
leukocytes is a complex process that requires the interaction
between several cell adhesion molecules (CAMs) and che-
mokines [144, 145]. The leukocytes roll on the endothelial
surface and then adhere to the endothelial cells, which leads
to diapedesis (Figure 1). The rolling of leukocytes is mediated
by interaction of E- and P-selectin (found on the surface
of endothelial cells), and L-selectin (normally found on the
surface of leukocytes) with their respective ligands [144].
Inhibiting the activity of P-selectin alone by treatment with
monoclonal antibodies (ARP 2–4, RMP-1) after the onset of
the insult does not reduce the infarct volume significantly
[146–148]. This suggests that the involvement of P-selectin
in the inflammatory response after ischemic injury starts
early. Firm adhesion and activation of leukocytes is mediated
by binding of the CD11/CD18 complex to CAMs, such as
intercellular cell adhesion molecule-1 (ICAM-1), vascular
cell adhesion molecule-1 (VCAM-1), platelet-endothelial cell
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adhesion molecule-1 (PECAM-1), and the mucosal address-
in [117, 144, 149]. Increased circulating levels of CAMs
have also been associated with aging, which could exacerbate
leukocyte infiltration [150]. IL-6 and TNF-α also regulate
the expression of CAMs on the endothelial cells and induce
infiltration of the ischemic penumbra by leukocytes at the
site of inflammation [144]. There is ample evidence from
animal models of MCAo that expression of CAMs is asso-
ciated with increased cerebral infarct size [144]. When MCAo
in experimental stroke was followed by reperfusion, adminis-
tration of anti-CAM antibodies decreased infarct size [151].
However, anti-CAM treatment has not been successful in
clinical studies of acute ischemic stroke. The enlimomab
study used a monoclonal antibody against ICAM-1, which
was administered within 6 hours of acute ischemic stroke
onset (Table 1). The three-month outcome mortality data
and adverse events were worse in the enlimomab group, and
it appears that there may have been a proinflammatory re-
sponse [28]. Surprisingly, for PECAM-1, there is suggestion
of possible neuroprotective properties aside from the neu-
rotoxic eects. PECAM-1 knock-out mice show facilitated
leukocyte transendothelial migration after histamine treat-
ment which contradicts the current hypothesis that PECAM-
1 stimulates migration [149]. Further research into therapeu-
tic targeting of CAM is ongoing [152, 153].
9. Inflammatory Cells in Acute Stroke
Neuroinflammation is characterized by an accumulation
of inflammatory cells and chemical mediators within the
cerebral infarct (Figure 1). Neutrophil infiltration in acute
stroke has been demonstrated by single photon emission
computer tomography (SPECT) studies [154]. This is asso-
ciated with increased cerebral infarct size [26]. A significant
inflammatory response has also been demonstrated in aged
animal models of stroke [33, 155]. Clinical studies have
shown that peripheral inflammatory cells also play an impor-
tant role in the pathogenesis of cerebral ischemia [26]. This
has also been demonstrated in numerous animal models of
acute stroke [92]. MRI animal studies have shown neutrophil
infiltration into the infarct zone within a few hours of ische-
mia, and this process peaks at 24 hours [156]. Blood-derived
macrophages and activated microglial cells contribute to the
postischemic brain damage by expressing iNOS and pro-
duction of cytotoxic agents and ROS [30]. Macrophage ac-
tivation has been shown to exacerbate cerebral injury in aged
animals [34]. How microglia become activated after ischemic
stroke is still not clear. A possible mechanism is rupture of
necrotic neurons in the core of the insult, leading to release
of their contents into the extracellular space and scavenging
of these contents by microglia [30]. Microglia/macrophages
surrounding the ischemic tissue will migrate toward the
ischemic lesion and engage in close contact with neurons
(“capping”). As these neurons die later on, this capping en-
sures early recognition and fast phagocytic removal of
dying/dead neurons [157]. In an activated state, microglia
will produce inflammatory and cytotoxic mediators con-
tributing to cell damage and cell death. On the other hand,
microglia are a major producer of TGF-β1 which supports
the hypothesis that microglial activation is also neuropro-
tective [25]. Finally, resident macrophages scavenge and
remove necrotic debris and harmful components. Indeed,
these data suggest that early activation is detrimental and
later activation beneficial. Dierent subsets of microglia may
have dierent roles after ischemic stroke and thus improve
or reduce the chances of survival of ischemic neurons
[158, 159]. Perhaps an ideal therapy should modulate the
microglial response in order to stimulate neurogenesis [160].
Transgenic mice in which microglial proliferation can be
inhibited (eliminated) show increased infarct volume (by
13%) after a 1-hour occlusion, which suggests that prolif-
erating resident microglial cells exert a neuroprotective role
after ischemia [161]. Microglial activation has also been
associated with stimulation of the toll-like receptor 4 (TLR4).
Permanent MCAo models of TLR4-deficient mice were
shown to have reduced infarct size [162]. TLR4 plays an
important role in the initiation of the inflammatory response
during cerebral ischemia and has become another important
target for neuroprotective therapy. However, TLR activity
seems to decline with aging, and further investigation into
its role in cerebrovascular disease is required [163].
Inhibition of leukocyte activation and infiltration into
the ischemic cerebral tissue have therefore been an important
area of neuroprotection drug research [152, 164]. The neu-
trophil inhibitory factor, UK-279, 276, a recombinant pro-
tein inhibitor of the CD11/CD18 receptor, demonstrated
reduced infarct size in animal models of stroke. However, the
Acute Stroke Therapy by Inhibition of Neutrophil (ASTIN)
study did not show any patient benefit and was terminated
for futility (Table 1) [48]. Neuroimaging studies have dem-
onstrated inflammatory cell infiltration during acute stroke
and identification of salvageable ischemic penumbra [165].
These imaging techniques can be used as important sur-
rogate markers for future anti-inflammatory drug studies.
The use of both neuroradiological markers and biomarkers
as surrogate measures of drug treatment in clinical stroke
trials is an important Stroke Treatment Academic Industry
Roundtable (STAIR) recommendation [8].
10. Free Radicals and Increased Oxidative Stress
Increased free radical production and oxidative stress play
an important role in the pathogenesis of both acute stroke
and senescence [21, 166]. Activated microglia/macrophages
further increase free radical generation and exacerbate
cerebral injury in aged-animal models of stroke [34]. This
is associated with mitochondrial dysfunction and results
in neuronal cell death [167]. Nitric oxide (NO) is one of
the important reactive oxygen species (ROS). It possesses
both neuroprotective and neurotoxic properties in cerebral
ischemia. This is related to the activation of the three dier-
ent isoforms of NO synthase (NOS) at dierent stages of the
ischemic process. The three isoforms of NOS are endothelial
(eNOS), neuronal (nNOS), and inducible (iNOS). NOS ca-
talyses the chemical conversion of L-Arginine to NO and
citrulline. The constitutive isoforms (eNOS and nNOS) are
activated by increased levels of intracellular calcium, during
8 Journal of Aging Research
the acute phase of cerebral ischemia. Neuronal NOS has
a much higher capacity for NO generation than eNOS, and
this is responsible for neuronal damage during the early
stages of ischemic stroke. Inducible NOS activation occurs
later, usually 12–48 hrs after the initial ischemic insult [85].
This is associated with a much higher production of NO, and
for a longer period, compared to its two isoforms.
The eect of eNOS is well known for its vasodilatory
properties, via the action of cyclic GMP. However, the activity
of eNOS has been shown to diminish in aged-animal models
[168]. Studies using eNOS knock-out mice have demon-
strated increased infarct size following transient MCAo
[169]. The upregulation of eNOS via the action of statins has
provided an additional neuroprotective property to this class
of lipid-lowering drugs [99]. On the contrary, nNOS knock-
out mice have been shown to develop smaller infarct volumes
in MCAo [170]. There is a strong association between
the activation of NMDA receptors and calcium-dependent
increase in nNOS activity. The toxic ROS, peroxynitrite
(ONOO −) produced from NO reactions has been associated
with neuronal cell death, via lipid peroxidation and DNA
damage [30, 171]. Increased expression of proapoptotic pro-
teins in aged animal stroke models, via constitutive NOS
activation, has also been associated with neuronal cell death
[172]. Inducible NOS upregulation results in further NO
generation during the later stages of cerebral ischemia [85].
Leucocytes and endothelial and glial cells are the main
sources of iNOS expression. Selective inhibitors of iNOS have
been shown to display neuroprotection for up to 5 days after-
ischemic insult [85]. Again, peroxynitrite is the main ROS
involved in neuronal cell death. Interactions between iNOS
and cyclo-oxygenase 2 (COX-2) have been linked to penum-
bral cell death in late cerebral ischemia [85]. Due to this late
and prolonged activation of iNOS, it remains an important
therapeutic target for potential antioxidant and spin-trap
agent therapy [173].
Another important source of ROS is NADPH oxidase.
This enzyme predominantly produces the superoxide anion,
which reacts with NO to generate peroxynitrite [166]. Re-
cently, there has been increasing interest in the role hydrogen
sulfide (H2S) in the pathogenesis of cerebral ischemia [174].
H2S is formed from the amino acid cysteine, via the action of
the enzyme cystathionine beta-synthase. However, H2S has
demonstrated both beneficial and detrimental eects during
acute cerebral ischemia [175, 176]. Clinical studies have dem-
onstrated worse neurological outcome in stroke patients with
higher plasma cysteine levels, reflecting increased H2S activ-
ity [175]. However, H2S has also demonstrated antioxidant
properties via free radical scavenging and inhibition of iNOS
[176, 177]. This dual eect of H2S could be related to the
dierent stages of cerebral ischemia, and more research is
required to investigate any potential therapeutic benefit of
targeting this molecular pathway [174].
Due to the destructive nature of ROS in cerebral is-
chemia, therapeutic interventions have been an important
area of translational stroke research. The increased oxidative
stress associated with aging may further exacerbate cerebral
ischemia and result in poor functional recovery in elderly
stroke patients [21, 167]. However, clinical studies using nat-
ural antioxidants (vitamin C and E) and B vitamins to lower
homocysteine have not shown any benefit in reducing vas-
cular risk [178, 179]. These vitamins also seem to have little
eect on the aging process, possibly because of low antiox-
idant activity at the smaller recommended doses [180].
The SAINT II [Stroke-Acute Ischemic—NXY-059 (Cerovive)
Treatment] study investigated the eect of the nitrone spin-
trap agent, NXY-059, in patients presenting within 6 hours
of acute stroke symptom onset [8]. This nitrone-derived free
radical trapping agent was shown to be an eective neuro-
protective agent in animal models of stroke, with a large ther-
apeutic window for treatment [181]. Unfortunately, results
from the phase III studies were negative, for both ischemic
and hemorrhagic stroke, and further development of the
drug has been abandoned (Table 1) [49]. However, lessons
from the SAINT studies have allowed further revision of the
STAIR criteria and will lead to more rigorous translational
research studies in the future [9, 181]. Research is ongoing
into antioxidant spin trap agents in the treatment of acute
stroke and senescence [21, 173].
Recent clinical studies of antioxidant agents have been
more encouraging and shown positive results in early clinical
stroke trials [51, 53] (Table 1). Edaravone (Radicut), a free
radical scavenger, is currently being investigated as an antiox-
idant agent in the treatment of acute stroke [182]. Edaravone
was shown to reduce activation of NF-κB and MMP-9 in
animal models of rt-PA-related hemorrhage [183]. This drug
was also shown to reduce oxidative neuronal damage [184].
Clinical studies have shown some benefits of edaravone in
lacunar stroke patients with reduction in infarct size and
early neurological recovery [51] (Table 1). Uric acid has also
been shown to have antioxidant activity and neuroprotective
eects in animal models of ischemic stroke [185]. Clinical
studies have demonstrated reduced levels of uric acid during
the acute phase of stroke, which may exacerbate oxidative
stress. The use of adjuvant uric acid treatment with rt-PA was
shown to reduce lipid peroxidation and may have beneficial
eects in patient outcome [53] (Table 1). Further clinical
trials of uric acid in acute stroke are being planned [54].
A viable alternative to conventional drug-based neuro-
protective therapies is brain/body cooling, or hypothermia.
This provides neuroprotection by reducing oxidative stress,
DNA damage, and neuronal apoptosis [186, 187]. In animal
studies of focal ischemia, short-term hypothermia consis-
tently reduces infarct size. Nevertheless, ecient neuropro-
tection requires long-term regulated lowering of whole body
temperature. Exposing poststroke-aged rats to a mixture of
air and a mild inhibitor of oxidative phosphorylation, H2S,
for 2 days, resulted in sustained, deep hypothermia (30.8 ±
0.7◦C). Long-term hypothermia led to a 50% reduction in
infarct size with a concomitant reduction in the number
of phagocytic cells. At the transcription level, hypothermia
caused a reduction in the mRNA coding for caspase 12,
NF-κB, and grp78 in the peri-infarcted region, suggesting
an overall decrease in the transcriptional activity related
to inflammation and apoptosis. Behaviorally, hypothermia
was associated with better performance on tests that require
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complex sensorimotor skills, in the absence of obvious
neurological deficits or physiological side eects, in aged rats
[188].
Mild-to-moderate intraischemic hypothermia reduces
ATP depletion, anoxic depolarization, glutamate release, and
apoptosis, maintains BBB integrity, inhibits white matter
injury, and blocks necrosis (if started during ischemia itself)
[189]. The eects of hypothermia on inflammation show a
more modulating response. However, hypothermia has been
suggested to only delay neuronal damage rather than to pro-
vide permanent protection. Furthermore, a distinction has to
be made between short and long cooling periods. It has been
suggested that the disadvantages of delayed cooling could be
overcome by performing a prolonged hypothermic protocol
[190]. However, the modulating influence of hypothermia
on neuroinflammation could also dier depending on these
parameters and requires further investigation [191]. Depth
and duration of cooling both influence outcomes in experi-
mental and clinical settings and may make translation to the
clinic dicult [192].
11. Blood-Brain Barrier Dysfunction
Cerebral ischemia is associated with the release of matrix
metalloproteinases (MMPs), as part of the neuroinflamma-
tory response. These proteases are involved in the breakdown
of the microvascular basal lamina, which results in the dis-
ruption of the BBB [193]. These changes are most prominent
in the core infarct, where neuronal damage is maximal. The
gelatinases (MMP-2 and MMP-9) are the main MMPs in-
volved in destruction of the basal lamina. MMP-2 is ex-
pressed constitutively in the CNS and is normally present
within cerebral tissue. MMP-9 is normally absent, and this is
the major MMP associated with neuroinflammation [194].
These enzymes are released from endothelium, glia, and in-
filtrating leukocytes. They target laminin, collagen IV, and
fibronectin proteins, which are the major constituents of the
basal lamina. This is associated with BBB dysfunction and
leads to cerebral edema [12]. Reduced infarct size has been
shown in rat models of stroke treated with MMP inhibitors,
and also in MMP-9 knock-out mice studies [195, 196].
MMP-9 levels play an important role in the development
of cerebral edema and hemorrhagic transformation of in-
farcted cerebral tissue [197]. Clinical studies have demon-
strated a strong correlation between elevated plasma MMP-9
levels and risk of hemorrhagic transformation in the acute
phase of ischemic stroke [197]. Elevated MMP-9 concen-
trations have also been shown to be a predictor of throm-
bolysis-related intracerebral hemorrhage in patients treated
with tissue plasminogen activator (t-PA) for acute ischemic
stroke [198]. The combination of MMP inhibitors with t-
PA could be a future treatment option in reducing bleeding
complications associated with thrombolytic therapy [173].
However, recent animal studies have demonstrated that
MMP inhibitors could worsen longer-term neurological out-
come, and further evaluation of these drugs in acute stroke
is required [199]. Broad-spectrum inhibitors of MMPs, such
as BB-94 and KB-R7785, administered after stroke onset,
reduce damage after permanent MCAo in mice by 26%
[200, 201]. Such treatments, however, cause serious side
eects due to their low specificity and explain why these
inhibitors have not been used in clinical practice [202]. On
that account, more selective inhibitors or knock-out mice for
MMP-2 or -9 have been explored. MMP-2 knock-out mice
subjected to 2-hour occlusion show massive upregulation of
MMP-9, and obviously no improvement could be observed
[203]. A selective inhibitor for MMP-2 and -9 (SB-3CT) in
mice subjected to a 2-hour MCAo reduces lesion size up to 6
hours after ischemia onset, and this inhibitor is well tolerated
in animals [202].
BBB dysfunction has been identified as a major cause of
cerebral injury in aged animal stroke models [52, 107]. After
ischemia, subtle dynamical changes in BBB permeability
occur and can be transient or permanent depending on the
severity of the insult. The latter is characterized by endothe-
lial swelling, astrocyte detachment, and blood vessel rupture
in the ischemic area, while transient BBB disruption shows
endothelial hyperpermeability to macromolecules in the
peri-infarct area [204]. Transient BBB disruption shows a
biphasic pattern with an initial opening 2-3 hours after the
onset of the insult, while 24–48 hours after reperfusion a sec-
ond opening occurs, leading to vasogenic edema and in-
creased intracranial pressure [204]. Furthermore, produc-
tion of proinflammatory cytokines and adhesion molecules
will be stimulated. Such a disruption results in rapid but sig-
nificant changes in the molecular relationship between astro-
cytes and the microvascular extracellular matrix, which has
a feedback eect on the neurons they supply and protect
[205]. BBB dysfunction in old age has been shown to be
closely related to white matter lesions and lacunar infarction
[206, 207]. Cerebral amyloid angiopathy is also associated
with BBB disruption in old age and subsequent increased risk
of intracerebral hemorrhage [208].
BBB permeability studies have demonstrated minimal
disruption within the first 6 hours after-MCAo but increased
permeability by 21 hrs [209]. However, this BBB dysfunction
occurs much earlier in aged rat models [107]. This was
examined by comparing young (3 months) and aged (18
months) MCAo rat models. BBB disruption was assessed at
20 min and 24 hrs after-MCAo, with t-PA-induced reperfu-
sion at 120 min. The results showed that BBB disruption in
aged rats occurred earlier and increased nearly twofold at
both 20 min and 24 hr time points compared to the younger
animals (Figure 2) [107]. Neuronal damage in aged rats was
also much worse compared to young rats at 24 hr, with
aged rats suering larger infarct size and reduced functional
recovery. These findings suggest that early BBB disruption
in aged stroke patients could contribute to a greater degree
of neuronal injury. There have been concerns that t-PA
treatment in elderly stroke patients may increase the risk of
hemorrhagic complications, but recent clinical studies have
shown no increased risk [210]. BBB dysfunction in old age is
therefore an important area of translational stroke research
[20, 210, 211]. The development of new MRI techniques for
investigating BBB dysfunction in stroke will be an impor-
tant investigational tool in future translational research
[212].
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Figure 2: Extravasation of albumin across the BBB 20 min after-
MCAO. The aged animals exhibited greater BBB permeability in
relation to the corresponding young rats in the infarcted hemi-
sphere (P < 0.001). (Copyright: DiNapoli et al. [107]).
12. Clinical Aspects of Neuroinflammation in
Acute Stroke
In addition to the development of the localized inflammatory
response in the brain, acute stroke also evokes an immune
response at the systemic level [15, 213]. This is characterized
by the release of proinflammatory mediators into the
systemic circulation [14, 15]. The clinical manifestation is
called the systemic inflammatory response syndrome (SIRS;
Table 2). SIRS is evident in both ischemic and hemorrhagic
stroke [214–216]. The degree of the inflammatory response
has also been shown to be related to the size of infarct volume
[13]. The inflammatory response is also associated with the
development of hyperthermia during the acute phase of
stroke [217]. This is related to stroke severity and associated
with poor patient outcome [217, 218]. Animal stroke models
have also demonstrated increased infarct size in hyperther-
mic conditions [219]. The neuroprotective eects of hypo-
thermia in animal stroke models have demonstrated reduced
activation of NF-κB and inflammatory pathways [124]. Clin-
ical research studies have also been investigating the neu-
roprotective eects of hypothermia, and further trials are
planned [125, 220]. The eects of antipyretic treatment in
hyperthermic acute stroke patients, as part of the Parac-
etamol (Acetaminophen) in Stroke (PAIS) trial, did not show
any benefit in stroke patients, but post hoc analysis of tem-
perature between 37 and 39◦C did show improved patient
outcomes with acetaminophen treatment [55] (Table 1). The
role of prophylactic antibiotic use in acute stroke patients,
in an attempt to treat associated infections and reduce in-
flammatory complications, is another area of ongoing re-
search [221]. Treatment with minocycline, a bacteriostatic
antibiotic with possible anti-inflammatory eects, has shown
beneficial eects in a pilot study of acute stroke patients
Table 2: The systemic inflammatory response syndrome (SIRS).
SIRS-diagnostic criteria
SIRS diagnosed if 2 or more of following criteria are present:
Temperature >38◦C or <36◦C
Respiratory rate >20 breaths/min
Heart rate >90 bpm
White cell count >12,000 mm3 or <4,000 mm3 or >10% immature
neutrophils
(Table 1), and further evaluation of this drug is ongoing
[56, 57].
The neuroinflammatory response has also been associ-
ated with cognitive decline and delirium, which is frequently
seen in elderly stroke patients [222, 223]. This seems to
compromise the reduced functional reserve in the aged brain
and is related to underlying cerebral small vessel disease
[4]. An increased cerebral inflammatory response has also
been demonstrated in aged animal studies with associated
increased cognitive deficits [35]. Increased CRP levels have
been associated with poststroke cognitive impairment in
elderly patients [224]. The reduction of this systemic inflam-
matory response could potentially improve cognitive and
functional outcomes in elderly stroke patients, and further
research of these eects in aged stroke animal models is
therefore important [181, 225]. With the increased risk of
stroke in postmenopausal females, hormonal eects in stroke
pathogenesis are also an important area of research. Many
preclinical stroke studies have demonstrated neuroprotective
and anti-inflammatory eects of estrogen [226]. However,
hormonal replacement therapy in female patients has been
associated with increased vascular risk in clinical studies
[226]. Male sex is an important risk factor for stroke, but
little is known about the eects of androgenic hormones in
stroke outcome. Some studies have shown that high testo-
sterone levels during the acute phase of stroke are associated
with worse clinical outcome but may have a neuroprotective
eect during the recovery phase [227]. However, clinical
studies show increased vascular risk associated with testos-
terone supplementation in older men, but this may have
some benefit in male patients with low testosterone levels
[228]. These contradictory results in preclinical and clinical
eects of sex hormone treatment therefore require further
translational research.
C-reactive protein (CRP) is an indicator of underlying
systemic inflammation. It is an acute-phase reactant and has
a pronounced rise in concentration after tissue injury or
inflammation. It does not seem to have a significant role in
the aging process per se but more related to disease pathogen-
esis [229, 230]. CRP has a long plasma half-life and could also
be a potential mediator as well as a marker of cerebrovascular
disease [231]. The association of increased levels of CRP with
ischemic stroke has been reported in several clinical studies
[15, 232]. It has been shown that increased levels of CRP are
associated with a worse outcome in patients with ischemic
stroke [232, 233]. Increased levels of CRP are also associated
with an increased risk of future stroke in elderly patients
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[90, 234]. However, the role of CRP in the pathogenesis of
ischemic stroke is not completely understood. It is unclear
whether CRP is just a marker of systemic inflammatory proc-
esses or directly involved in pathogenesis of cerebral tissue
damage [231]. Further research to investigate any potential
therapeutic benefits of inhibiting CRP in vascular disease is
ongoing [235].
13. Conclusion
The incidence of stroke is highest in the elderly population,
and the underlying pathogenic changes in combination with
senescence have been associated with increased cerebral
injury [11]. Acute cerebral ischemia results in a complex
inflammatory cascade resulting in the activation of a variety
of inflammatory cells and molecular mediators. Aged animal
models have demonstrated a more intense inflammatory re-
sponse during the acute phase of ischemia, followed by early
scar formation and fibrosis. There is also earlier BBB dys-
function in older animals with increased permeability and
neuronal injury. The neuroinflammatory response involves
several molecular pathways, which are interconnected with
the aging process and cognitive dysfunction. These complex
molecular interactions in old age make it dicult to draw
firm conclusions from research observations made in young
animal models of stroke and translate these findings into
clinical studies. The importance of conducting preclinical
stroke studies in aged animal models will therefore be an
important part of translational stroke research (STAIR cri-
teria) in the future [6, 8].
Numerous animal models of stroke have demonstrated
reduced infarct size on modification of the inflammatory re-
sponse although these inflammatory mediators also have
beneficial eects during the recovery phase. Clinical studies
have suggested that cerebral infarct size and patient outcome
are aected by the inflammatory response. Unfortunately,
clinical neuroprotective drug trials targeting the inflamma-
tory pathways in acute ischemic stroke have thus far been
disappointing. Most of the preclinical stroke studies have
been performed in young animal models and therefore do
not reflect the molecular changes associated with the aged
brain. This has been one of the criticisms of preclinical stroke
neuroprotection studies and implicated in the failure of clin-
ical trials. A more rigorous bench-to-bedside research ap-
proach into investigating neuroprotective agents in a target
elderly stroke population may allow a more successful tran-
sition into clinical trials and hopefully clinical practice [8,
181]. A multitarget approach together with reperfusion
therapies may be the best therapeutic approach in the future.
There is sucient data to support that hypothermia
acts at multiple levels of the ischemic cascade and of the
neuroinflammatory response. Hypothermia attenuates the
expression of several inflammatory mediators at certain time
points and appears to be an attractive therapeutic option, but
more research is required to discern which positive or neg-
ative eects contribute to neuroprotection [236]. The abil-
ity of hypothermia to modulate many aspects of the in-
flammatory response may render translation to the clinic
feasible [125]. Another advantage of hypothermia could be
the creation of a larger therapeutic time window to adminis-
ter other neuroprotective agents and thus improve outcome
after transient focal cerebral ischemia. With the success of
thrombolysis in the treatment of acute ischemic stroke and
ongoing clinical trials of interventional reperfusion thera-
pies, together with better MR imaging techniques, adjuvant
neuroprotective therapies remain an attractive option in the
future [27, 29].
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